Great Lakes Advisors LLC Acquires Shares of 29,800 Supernus Pharmaceuticals, Inc. $SUPN

Key Points

• Great Lakes Advisors LLC acquired 29,800 shares of Supernus Pharmaceuticals in the second quarter, worth approximately $1.39 million and representing about 0.05% of the company.
• Supernus reported quarterly revenue of $219.1 million, up 32.4% year over year and above estimates, but its adjusted earnings of negative $1.01 per share missed consensus by $1.43.
• Shares opened at $45.85, down 3.4%, while analyst sentiment remained a “Moderate Buy” with an average price target of $62.83.

Great Lakes Advisors LLC acquired a new stake in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 29,800 shares of the specialty pharmaceutical company's stock, valued at approximately $1,386,000. Great Lakes Advisors LLC owned about 0.05% of Supernus Pharmaceuticals at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently made changes to their positions in SUPN. Royal Bank of Canada lifted its position in Supernus Pharmaceuticals by 68.1% in the 1st quarter. Royal Bank of Canada now owns 11,669 shares of the specialty pharmaceutical company's stock valued at $382,000 after acquiring an additional 4,729 shares in the last quarter. AQR Capital Management LLC increased its holdings in Supernus Pharmaceuticals by 35.2% during the 1st quarter. AQR Capital Management LLC now owns 85,224 shares of the specialty pharmaceutical company's stock worth $2,791,000 after purchasing an additional 22,182 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in shares of Supernus Pharmaceuticals by 4.5% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 29,860 shares of the specialty pharmaceutical company's stock worth $978,000 after purchasing an additional 1,297 shares during the last quarter. Millennium Management LLC raised its stake in shares of Supernus Pharmaceuticals by 370.5% in the first quarter. Millennium Management LLC now owns 143,356 shares of the specialty pharmaceutical company's stock worth $4,695,000 after purchasing an additional 112,886 shares during the last quarter. Finally, Empowered Funds LLC lifted its holdings in shares of Supernus Pharmaceuticals by 16.0% in the first quarter. Empowered Funds LLC now owns 48,045 shares of the specialty pharmaceutical company's stock valued at $1,573,000 after purchasing an additional 6,619 shares in the last quarter.

Supernus Pharmaceuticals Trading Down 3.4%

Shares of SUPN opened at $45.85 on Friday. The company has a market capitalization of $2.67 billion, a price-to-earnings ratio of -23.88, a PEG ratio of 0.87 and a beta of 0.56. The stock has a 50 day moving average of $46.74 and a 200 day moving average of $48.82. Supernus Pharmaceuticals, Inc. has a 12 month low of $42.45 and a 12 month high of $59.68.

Supernus Pharmaceuticals (NASDAQ:SUPN - Get Free Report) last announced its earnings results on Monday, August 3rd. The specialty pharmaceutical company reported ($1.01) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.42 by ($1.43). Supernus Pharmaceuticals had a positive return on equity of 11.13% and a negative net margin of 13.23%.The business had revenue of $219.06 million for the quarter, compared to analyst estimates of $205.31 million. During the same quarter in the previous year, the company earned $0.40 EPS. The business's revenue for the quarter was up 32.4% on a year-over-year basis. As a group, equities research analysts predict that Supernus Pharmaceuticals, Inc. will post 1.97 earnings per share for the current year.

Wall Street Analysts Forecast Growth

SUPN has been the subject of several recent research reports. Wall Street Zen downgraded Supernus Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Saturday, August 8th. Zacks Research upgraded Supernus Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a research note on Thursday, August 6th. Weiss Ratings reaffirmed a "sell (d+)" rating on shares of Supernus Pharmaceuticals in a report on Wednesday, June 24th. Finally, Cantor Fitzgerald upped their target price on shares of Supernus Pharmaceuticals from $63.00 to $67.00 and gave the stock an "overweight" rating in a research note on Thursday, July 9th. One investment analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $62.83.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, headquartered in Rockville, Maryland, is a specialty pharmaceutical company dedicated to developing and commercializing central nervous system (CNS) therapies. Since its founding in 2003, Supernus has focused on advancing treatments for neurological disorders, with an emphasis on improving patient quality of life through innovative dosage forms and sustained‐release formulations.

The company's marketed portfolio includes Trokendi XR and Oxtellar XR, extended‐release antiepileptic medications designed to maintain stable drug levels for seizure control, as well as Qelbree (viloxazine extended‐release capsules), approved for the treatment of attention‐deficit/hyperactivity disorder (ADHD) in pediatric and adult patients.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source